November 7, 2025 7:55am

Buy dips as sector earnings surpassed, met, beat or missed expectations with whipsaw depreciations actions ensuing as the stock market headed south; with “blood on the street” time to “dip one’s toes” into the C&GT sector

Counting: 7 negatives and 2 positive closes out of 9 sessions – We’re Due!

Earnings today: Cellectis SA (CLLS) and Prime Medicine (PRME)

Pre-open Signals: 7 Negative, 1 Positive Indications

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

TGIF

“I hate to be considered negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Thursday’s RMi Closing Bell: Tumble … https://www.regmedinvestors.com/articles/14185   

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

 

Friday: The pre-open Dow futures are DOWN -0.29% or (-135 points), the S&P futures are DOWN -0.39% or (-26 points) and the Nasdaq futures are DOWN -0.53% or (-134 points)

  • Stock futures are falling and weak on Friday, 11/7
  • European markets declined, extending losses
  • Asia Pacific markets fell as China’s October imports and exports missed expectations.

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Thursday: The Dow closed DOWN -398.70 points or -0.84%, the S&P closed DOWN -75.97 points or -1.12% while the Nasdaq closed DOWN -445.805 points or -1.90%
  • Wednesday: The Dow closed UP +225.86 points or +0.48%, the S&P closed UP +24.74 points or +0.37% while the Nasdaq closed UP +151.16 points or +0.65%
  • Tuesday: The Dow closed DOWN -251.07 points or -0.53%, the S&P closed DOWN -80.30 points or -1.17% while the Nasdaq closed DOWN -486.087 points or -2.04%
  • Monday: The Dow closed DOWN -226.19 points or -0.48%, the S&P closed UP +11.77 points or +0.17% while the Nasdaq closed UP +109,766 points or +0.46%
  • Last week: The S&P 500 was up 1.5%, the Dow +0.9% and the Nasdaq is up +3.2%
  • The previous week: the S&P 500 was up +2%, the Dow +2% and the Nasdaq added +2%.
  • Last month: the S&P 500 was up +2.3%, the Nasdaq’s +4.7% and the Dow’s is up +2.5%.
  • 2025 to date: the S&P is up +16%, the Nasdaq +22% and thew Dow +12%

 

Q4 – November, 1 positive and 3 negative sessions

  • October, 1 neutral, 10 positive and 12 negative closes
  • Q3 – September, 1 holiday, 9 negative and 12 positive closes; August - 11 negative and 9 positive closes; July – 1 market holiday, 13 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Alnylam Pharmaceuticals (ALNY) closed up +$5.93 after Wednesday’s +$11.09, Tuesday’s -$10.45 and Monday’s -$22.1 with a negative -$1.49 or -0.34% pre-open,

Lenz Therapeutics (LENZ) closed up +$1.49 after Wednesday’s -$6.58, Tuesday’s +$0.12 and Monday’s -$1.79 with a negative -$0.06 or -0.26% pre-open

uniQure NV (QURE) closed up +$1.45 after Wednesday’s -$4.38, Tuesday’s -$3.85 and Monday’s -$33.40 with a negative -$0.61 or -2.22% pre-open

Moderna (MRNA) closed up +$0.77 after Wednesday’s -$0.19, Tuesday’s -$1.16 and Monday’s -$2.25 with a negative -$0.21 or -0.86% pre-open

Intellia Therapeutics (NTLA) closed down -$1.25 after Wednesday’s +$1.37 with a negative -$3.72 or -29.63% pre-open

Sarepta Therapeutics (SRPT) closed down -$1.03 after Wednesday’s +$2.47, Tuesday’s -$8.25 and Monday’s +$0.44 with a negative -$0.19 or -1.08% pre-open

Vertex (VRTX) closed down -$0.75 after Wednesday’s -$4.67 after Tuesday’s -$4.33 and Monday’s +$0.43 with a positive +$0.69 or +0.16% pre-open

Arrowhead Pharma (ARWR -$0.71 after Wednesday’s +$2.46, Tuesday’s -$1.76 and Monday’s -$2.78 with a negative -$0.52 or -1.31% pre-open

 

 

The BOTTOM LINE: Still feeling the drag…

The 4th trading day of November began on another negative after a positive note

  • As the government shutdown continues becoming the longest in American history.
  • A rough trading session that saw all 3 indexes closing in the green

I got on my computer/laptop/ my horse with a lantern as I ride yelling … “earnings are here, earnings are here”!

Q3 Earnings coming: followed by uniQure NV (QURE) and Capricor Therapeutics (CAPR) on 11/10, Precigen (PGEN) on 11/13 and Arrowhead Pharma (ARWR) FY25 results on 11/25

Expect earnings’ results that meet, beat or miss revenue estimates, EPS as to pricing expectations, consensus … sector earnings while LPS (loss-per-share) assumes adjustments

Welcome to my world of defining the “grey’ in our universe!

  • As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

November to understand the flow review some of October:

New week and month, November:

  • 11/6 – Thursday closed negative with 15 positive, 24 negative and 1 flat
  • 11/5 - Wednesday closed positive with 20 positive, 18 negative and 2 flats
  • 11/4 – Tuesday closed negative with 10 positive, 30 negative and 0 flat
  • 11/3 – Monday closed negative with 10 positive, 26 negative and 4 flats

Last week:

  • 10/31 – Friday closed positive with 28 positive, 11 negative and 1 flat
  • 10/30 – Thursday closed negative with 13 positive, 25 negative and 2 flats
  • 10/29 - Wednesday closed negative with 9 positive, 30 negative and 1 flat
  • 10/28 -Tuesday closed negative with 16 positive, 21 negative and 3 flats
  • 10/27- Monday closed negative with 18 positive, 22 negative and 0 flats

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.